FDA OKs 1st generic nasal spray of overdose reversal drug
U.S. regulators have approved the first generic nasal spray version of Narcan, a drug that reverses opioid overdoses.
The Food and Drug Administration on Friday OK'd naloxone spray from Israel's Teva Pharmaceuticals.
Naloxone has been sold as a nasal spray in the U.S. since 2016 under the brand name Narcan. Pharmacists can dispense it without a prescription. It is also sold as a generic or brand-name drug in automatic injectors, prefilled syringes and vials.
A pack of two Narcan nasal sprays cost about $130 to $150 without insurance. Teva didn't immediately provide the product's price or when it will be available; its offices were closed Friday.
More than 47,600 Americans died of opioid overdoses in 2017, a toll that has been rising for two decades.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
As 2022 ends, still no visible progress on Comite and Amite river...
Dog stayed with missing Louisiana girls for hours after they got lost...
Sources: WBR sheriff's office employee took cash for ticket but never cleared...
Charities hoping more donations come in as Giving Tuesday wraps up
EBR school system asking for people to Adopt an Elf this holiday...
Southeastern hosting Idaho in first round of FCS Playoffs Saturday
Fans' Choice Award Winner: U-High's Keylan Moses
Southeastern running back Derrick Graham has a deep passion for rodeo
Southeastern to face Idaho in first round of FCS Playoffs
The Black and Gold Report: New Orleans Saints vs Los Angeles Rams